18FDG-PET/CT in staging and measuring the efficacy of neoadjuvant chemotherapy in breast cancer

被引：1
作者：
Groheux, D. [1 ,2 ]
Hindie, E. [3 ,4 ]
机构：
[1] Hop St Louis, Nucl Med Serv, F-75475 Paris 10, France
[2] Ctr Imagerie Radioisotop, F-17000 La Rochelle, France
[3] CHU Bordeaux, Hop Haut Leveque, Nucl Med Serv, F-33000 Bordeaux, France
[4] Univ Bordeaux, F-33000 Bordeaux, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2015年 / 39卷 / 03期
关键词：
(18)FDG; PET/CT; Breast cancer; Staging; Prognosis; Neoadjuvant treatment; Response assessment; Pathological complete response; Triple-negative breast cancer; HER2-positive breast cancer; ER-positive breast cancer; POSITRON-EMISSION-TOMOGRAPHY; PATHOLOGICAL COMPLETE RESPONSE; EARLY METABOLIC-RESPONSE; LONG-TERM SURVIVAL; F-18-FDG PET/CT; FDG-PET/CT; EARLY PREDICTION; OPEN-LABEL; PREOPERATIVE CHEMOTHERAPY; BLOOD-FLOW;
D O I：
10.1016/j.mednuc.2015.03.003
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Accurate staging is of importance for taking appropriate management decisions in a patient with newly diagnosed breast cancer. The role of (18)FDG-imaging in detecting extra-axillary lymph node involvement and distant lesions in high-risk breast cancer patients is highlighted. This review also discusses potential roles of (18)FDG-PET/CT in early assessing response to neoadjuvant chemotherapy. Interim-PET/CT received increased attention in recent years through pilot studies exploring its role in specific subtypes of breast cancer. Results of a French trial that used early metabolic response with (18)FDG-PET/CT as a means to select poor responders for intensification have been recently published, with encouraging results. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：315 / 326
页数：12
相关论文
共 108 条
  • [1] 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Imaging in the Staging and Prognosis of Inflammatory Breast Cancer
    Alberini, Jean-Louis
    Lerebours, Florence
    Wartski, Myriam
    Fourme, Emmanuelle
    Le Stanc, Elise
    Gontier, E.
    Madar, O.
    Cherel, P.
    Pecking, A. P.
    [J]. CANCER, 2009, 115 (21) : 5038 - 5047
  • [2] Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade, W. P.
    Lima, E. N. P.
    Osorio, C. A. B. T.
    do Socorro Maciel, M.
    Baiocchi, G.
    Bitencourt, A. G. V.
    Fanelli, M. F.
    Damascena, A. S.
    Soares, F. A.
    [J]. EJSO, 2013, 39 (12): : 1358 - 1363
  • [3] [Anonymous], 2014, BREAST CANC VERS 3
  • [4] Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer
    Aukema, Tjeerd S.
    Straver, Marieke E.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Russell, Nicola S.
    Gilhuijs, Kenneth G. A.
    Vogel, Wouter V.
    Rutgers, Emiel J. T.
    Olmos, Renato A. Valdes
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (18) : 3205 - 3210
  • [5] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    [J]. LANCET, 2012, 379 (9816) : 633 - 640
  • [6] Breast Cancer: Comparative Effectiveness of Positron Emission Mammography and MR Imaging in Presurgical Planning for the Ipsilateral Breast
    Berg, Wendie A.
    Madsen, Kathleen S.
    Schilling, Kathy
    Tartar, Marie
    Pisano, Etta D.
    Larsen, Linda Hovanessian
    Narayanan, Deepa
    Ozonoff, Al
    Miller, Joel P.
    Kalinyak, Judith E.
    [J]. RADIOLOGY, 2011, 258 (01) : 59 - 72
  • [7] [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
    Berriolo-Riedinger, Alina
    Touzery, Claude
    Riedinger, Jean-Marc
    Toubeau, Michel
    Coudert, Bruno
    Arnould, Laurent
    Boichot, Christophe
    Cochet, Alexandre
    Fumoleau, Pierre
    Brunotte, Francois
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) : 1915 - 1924
  • [8] Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography
    Bos, R
    van der Hoeven, JJM
    van der Wall, E
    van der Groep, P
    van Diest, PJ
    Comans, EFI
    Joshi, U
    Semenza, GL
    Hoekstra, OS
    Lammertsma, AA
    Molthoff, CFM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 379 - 387
  • [9] Calibration Test of PET Scanners in a Multi-Centre Clinical Trial on Breast Cancer Therapy Monitoring Using 18F-FLT
    Bouchet, Francis
    Geworski, Lilli
    Knoop, Bernd O.
    Ferrer, Ludovic
    Barriolo-Riedinger, Alina
    Millardet, Corinne
    Fourcade, Marjolaine
    Martineau, Antoine
    Belly-Poinsignon, Anne
    Djoumessi, Francis
    Tendero, Karine
    Keros, Laurent
    Montoya, Frederic
    Mesleard, Christel
    Martin, Anne-Laure
    Lacoeuille, Franck
    Couturier, Olivier
    [J]. PLOS ONE, 2013, 8 (03):
  • [10] Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis
    Buchbender, Christian
    Heusner, Till A.
    Lauenstein, Thomas C.
    Bockisch, Andreas
    Antoch, Gerald
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (06) : 928 - 938
12345678910